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Abstract
Background: Seasonal influenza has been associated with greater morbidity and mortality in AIDS patients. Highly-active
antiretroviral therapy (HAART) has led to some reduction in influenza-related complications but the nature of naturally-
acquired T-cell immunity to influenza virus in an African setting, and how this changes with immune reconstitution
following HAART is unknown. We measured influenza-specific CD4+ T-cell immunity in unimmunized HIV-infected Malawian
adults and then investigated immune reconstitution following HAART.
Methods: Peripheral blood mononuclear cells were isolated from HIV-infected and HIV-uninfected Malawian adults. CFSE
proliferation and CD154 expression flow cytometry-based assays were used to measure influenza-specific CD4+ T-cell
immunity.
Results: We found lower naturally-acquired proliferative influenza-specific CD4+ T-cell responses in AIDS patients that was
also present in asymptomatic HIV-infected adults with relatively high CD4 counts (.350 cells/ml). Influenza-specific CD4+ T-
cell immune reconstitution in HIV-infected patients on HAART for 12 months was poor despite a marked reduction in viral
load and an increase in CD4 count. This poor immune reconstitution was characterised by a low influenza-specific
proliferative CD4+ T-cell response and reduced proportions of CD154-expressing influenza-specific CD4+ T-cells in peripheral
blood.
Conclusion: Our data suggest that asymptomatic HIV-infected adults may also be at risk of influenza-related complications
and that HAART alone may not circumvent this risk in AIDS patients. This study highlights the need to identify possible
interventions early in HIV infection to reduce the risk of influenza and to intensify influenza surveillance in these susceptible
African populations.
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Introduction
Influenza virus causes 0.5 million deaths each year and due to
the emergence of new reassortants such as the 2009 H1N1
pandemic influenza A virus, are able to escape immune
surveillance, thus posing a major threat to global health [1]. Most
of the data on the burden of influenza infection and the
characteristics of naturally-acquired immunity have emerged from
Europe, North America and Southeast Asia [1]. Very little has
been reported from sub-Saharan Africa (SSA), home to two-thirds
of world’s people living with HIV [2].
There is conflicting data regarding HIV as one of the risk
factors for more severe disease and death in influenza patients
[3,4]. One of the possible reasons for the discrepancies in the
studies has been the sample size, as most of the studies have been
underpowered to address this question and have mostly been done
in western countries. Recently, there has been a study from South
Africa by Cohen et al. that has shown that there is an increased risk
of death and longer mean duration of hospitalisation amongst
HIV-infected persons hospitalised with influenza-confirmed illness
than HIV-uninfected counterparts [Conference paper].
In industrialised countries, the introduction of highly-active
antiretroviral therapy (HAART) has led to some reduction in
influenza-associated complications among HIV-infected persons,
which appears to be related to the increase in CD4 count [5]. In
the context of a potential influenza epidemic in sub-Saharan
Africa affecting large numbers of HIV infected individuals [6], the
risk associated with HIV infection among those with relatively less
immune suppression remains to be elucidated.
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CD4+ T-cells are important in anti-influenza defence, they
provide help to B-cells which leads to production of antibodies
necessary to complete viral clearance [7]. They also promote the
generation of memory influenza-specific CD8+ T-cells which help
in clearing secondary influenza infections [8]. We have previously
demonstrated strong naturally-acquired mucosal and systemic
CD4+ T-cell immune memory to influenza antigens in healthy UK
adults [9]. We have also shown that asymptomatic HIV-infected
African adults have considerable signs of immune dysregulation
with impaired influenza-specific CD4+ T-cell responses in the lung
[10]. Here we further describe nature of systemic naturally-
acquired CD4+ T-cell immunity in an African setting and assess
how this changes with immune reconstitution with HAART. We
observed a robust influenza-specific immunity in healthy African
adults, which was lost in HIV-infected adults and was not restored
even after 12months on HAART.
Materials and Methods
Ethical approval
The research described fulfil all institutional guidelines and was
approved by the College of Medicine Bioethics Committee,
Malawi (P.03/08/626 and P.01/09/717) and The Liverpool
School of Tropical Medicine Research Ethics Committee (08.41
and 08.61.).
Subjects
Two cohorts of adults with no recent history of severe
respiratory diseases were recruited at the Queen Elizabeth Central
Hospital (QECH), Blantyre, Malawi: a cohort of HIV-uninfected
adults and asymptomatic HIV-infected individuals who were
sampled once (cross-sectional cohort); and a cohort of HIV-
infected adults about to start HAART (WHO stage 3/4) who were
sampled just before starting HAART and sampled again 6months
and 12months after starting HAART (longitudinal cohort).
According to national guidelines, the commencement of HAART
in Malawi is currently mostly based on clinical WHO staging
rather than CD4 count. All participants gave written-informed-
consent to HIV testing and blood collection. The exclusion criteria
for the study were: use of immunosuppressive drugs, moderate or
severe anaemia (HB,8 g/dl) and known or possible pregnancy.
The influenza immunity data from HIV-uninfected adults and
asymptomatic HIV-infected individuals has been reported in part
previously [11].
Assessment of influenza-specific CD4+ T-cell immunity
Peripheral blood mononuclear cells (PBMCs) were processed as
previously described [12]. Influenza-specific CD4+ T-cell immune
responses were determined using Carboxyfluorescein succinimidyl
ester (CFSE) proliferation and CD154 (CD40L) expression assays.
In all the assays, PBMCs were stimulated with 2008/2009
Inactivated Influenza vaccine (Split virion) BP (Sanofi Pasteur
MSD, UK) (0.45–0.9 mg/ml) (the vaccine contains antigens
equivalent to the following strains; A/Brisbane/59/2007
(H1N1)-like strain IVR-148 derived from A/Brisbane/59/2007,
A/Brisbane/10/2007 (H3N3)-like strain NYMC X-175C derived
from A/Uruguay/716/2007 and B/Florida/4/2006-like strain B/
Florida/4/2006) as the test antigen or phytohemagglutinin (PHA)
(0.5–4 mg/ml) as the positive control. Due to limitations in cell
numbers, not all the assays were done on all the volunteers.
Proliferation of CD4+ T-cells was measured by flow cytometry
after a CFSE dilution assay as previously described [11]. Briefly,
PBMC were stained with CFSE, stimulated with antigens or left
unstimulated, harvested after 7 days, surface-stained with anti-
human CD3 Peridinin Chlorophyll Protein Complex (PercP) and
CD4 allophycocyanin (APC) (All BD Biosciences), and acquired
on a CyAn flow cytometer (Beckman Coulter, USA).
CD154 expression was measured using a co-culture method as
described previously [11]. Briefly, PBMCs were co-cultured with
anti-CD154-PE antibody (BD Biosciences), stimulated with
antigens or left unstimulated for 16 hours, harvested, surface-
stained with anti-CD3 Fluorescein isothiocyanate (FITC), anti-
CD4-PerCP, anti-CD69-APC and anti-CD154-PE (BD Bios-
ciences), and acquired on a flow cytometer. FACS analysis was
done using FlowJo (Tree Star, USA).
Statistical analyses
Statistical analyses and graphical presentation were done using
GraphPad Prism 5 (GraphPad Software, USA). The data were
analyzed using the Mann-Whitney U test (non-paired data) and
Wilcoxon signed-ranked test (paired data). Results are given as
medians with interquartile ranges (IQRs). Differences were
considered statistically significant where p#0.05.
Results
Demographic characteristics
In the cross sectional cohort, 31 HIV-uninfected adults (32%
female; median age 33years(23–53)) and 31 asymptomatic HIV-
infected patients (46% female; median age 31years(18–58)) were
recruited. The median CD4 count in HIV-uninfected adults was
853cells/ml(444–1323) and in the asymptomatic HIV-infected
patients was 252cells/ml(7–913). In the longitudinal HAART
cohort, 10 HIV-uninfected adults (35% female; median age
31years(24–56)) and 16 HIV-infected patients about to commence
HAART (56% female; median age 37years(25–55)) were enrolled.
The median CD4 count in HIV-uninfected adults was 602cells/
ml(531–763) and HIV-infected patients about to commence
HAART was 160cells/ml(79–227) which increased to 249cells/
ml(189–360) at 6months on HAART (p,0.0001), but did not
significant increase at 12months (249cells/ml(189–360) vs.
274cells/ml(197–370); p.0.05). The viral load was either un-
detectable or below 5000 copies/ml in all participants at 6 months.
None of the participants in either cohort had been vaccinated
against influenza.
Poor influenza-specific proliferative CD4+ T-cell
responses in HIV-infected adults irrespective of CD4
count
We evaluated the proliferative capacity of CD4+ T-cells in
response to influenza antigens. We found that the influenza-
specific proliferative CD4+ T-cell responses in the HIV-infected
adults with CD4 count.350 were lower than those of HIV-
uninfected individuals (1.44%[0.5–2.9] vs. 4.78%[1.4–10.9];
p = 0.03) (Figure 1). The influenza-specific proliferative CD4+
T-cell responses in HIV-infected patients were similar between
those that had a CD4 count.350 and those with a CD4
count,350 (0.76%[0.1–3.2] vs. 1.44%[0.5–2.9]; p.0.05)
(Figure 1). However, this impairment in CD4+ T-cell proliferative
responses was not observed in response to polyclonal stimulation
(PHA) confirming that there was no intrinsic defect in function of
CD4 T-cells from HIV-infected individuals (Figure S1).
Poor immune reconstitution of Influenza-specific CD4+ T-
cell responses in HIV-infected patients following HAART
Following the observations that influenza-specific proliferative
responses were impaired in HIV-infected patients, we investigated
Poor Influenza T-Cell Responses in HIV+ Adults
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whether HAART reversed this immune defect. The proliferative
influenza-specific responses at 12months following HAART were
lower than HIV-uninfected individuals (1.9%[1.1–7.4] vs.
14.7%[7.2–23.2]; p = 0.04). The proliferative influenza-specific
responses in HIV-infected patients at 6months following HAART
were similar with those detected at baseline (3.3%[0.6–8.3] vs.
2.5%[0.0–10.2]; p.0.05), and did not differ with those detected at
12months (3.3%[0.6–8.3] vs. 1.9%[1.1–7.4]; p.0.05) (Figure 2A).
There was no association between CD4 nadir or viral load and
antigenic proliferative response at baseline, 6months or 12months
(p.0.05 for all) (data not shown).
We also measured CD154 expression, pre- and post-HAART.
CD154 is an important molecule expressed on activated antigen-
specific CD4+ T-cells and is involved in activation of antigen-
presenting cells, priming of CD4+ T-cells, B-cell proliferation and
immunoglobulin synthesis. Due to its various functions, CD154 it
likely to play an important role in defence against influenza
infection. Induction of CD154 in response to microbial pathogens
is impaired in CD4+ T cells from HIV-infected patients and this
has been associated with increased susceptibility to these
pathogens [13]. CD154 can also be used as marker to detect the
proportion antigen-specific CD4+ T-cell s, as it is expressed on
recently activated antigen-specific cells following stimulation with
cognate antigens [14]. We found some degree of immune
reconstitution in the frequency of activated influenza-specific
CD4+ T-cells expressing CD154 in HIV-infected patients follow-
ing 6 months on HAART (0.0%[0.0–0.03] vs. 0.03%[0.0–0.06];
p = 0.03), however, the frequency was still lower than HIV-
uninfected individuals (0.03%[0.0–0.06] vs. 0.1%[0.06–0.2];
p = 0.001) (Figure 2B).
Discussion
Pandemic influenza A has had devastating effects amongst
young fit adults [15], however, typically the very young, the very
old, pregnant women and immunocompromised individuals have
had the worst outcome [16]. In many industrialised countries these
at-risk groups are targeted for influenza vaccination. We have
demonstrated widespread influenza-specific CD4+ T-cell immuni-
ty in a healthy African adult population, which is impaired in
HIV-infected individuals even after immune reconstitution with
HAART for 12months.
Outside South Africa [17], there is limited information on the
prevalence of influenza virus infections. The observation that there
is widespread robust influenza-specific immunity in healthy
Malawian adults and indeed children (unpublished data) in the
absence of vaccination, suggests that there is considerable
exposure to influenza virus in this population. These African
adults had similar immunity to their counterparts in industrialised
countries where prevalence of influenza infections are high [18].
CD4+ T-cells generated from priming with seasonal influenza
viruses and vaccines cross-react with antigens derived from
pandemic H1N1 virus [19]. Although the influenza-specific
CD4+ T-cells generated from seasonal influenza strains might
provide some degree of cross-protection to pandemic strains, the
uncertainty of the extent and geographical spread of influenza
infection in this population poses a major challenge to pre-
paredness to a potential influenza pandemic.
In contrast to the influenza-specific CD4+ T-cell immunity
observed in the HIV-uninfected group, we observed impaired
influenza-specific CD4+ T-cell proliferative responses in HIV-
infected individuals, a measure of central memory [20]. We have
previously shown that HIV-infected adults had no depreciation in
peripheral blood influenza-specific cytokine-secreting effector
memory CD4+ T-cells. This variance in results from the two
different assay is consistent with the evidence that there is
preferential depletion of central memory versus effector memory T
cells in HIV-infected adults [11,21]. We speculate, therefore, that
the influenza-specific proliferative CD4+ T-cell responses are
impaired earlier than effector responses during HIV infection.
Interestingly, we found that influenza-specific CD4+ T-cell
function was already lost in individuals with relatively high CD4
count and no association was found between CD4 count and
influenza-specific proliferative responses, showing that defects in
influenza-specific CD4+ T-cell proliferative response happens
early in HIV-infection before a global depletion of CD4+ T-cells.
Given the likely effects on antigen presentation and antibody
mediated immunity [22,23], the implications of poor influenza
immunity in HIV-infected individuals goes beyond the potential
threat of an H1N1 epidemic [1]. Epidemiological evidence and
mouse infection models suggest that influenza predisposes to
a range of invasive bacterial infections, including pneumococcal
pneumonia [24]. Impaired influenza-specific immunity in early
HIV infection in an area of intense pneumococcal exposure may
contribute to increased incidences of pneumococcal disease. Most
likely any vaccine intervention will need to be introduced early in
the course of HIV infection in order to circumvent the risk of
influenza-related bacterial complications.
Although HAART has helped in reducing morbidity and
mortality due to influenza-related complications in some popula-
tions [5], influenza virus is still among the leading causative agents
of febrile respiratory illnesses among HIV-infected outpatients on
Figure 1. Impaired influenza virus antigen-specific CD4+ T-cell
proliferative responses in peripheral blood of HIV-infected
adults. (A) Peripheral blood mononuclear cells were stained with CFSE,
stimulated with influenza vaccine for 7 days and proliferative responses
were measured using flow cytometry. Black horizontal bars represent
median and IQRs after background responses were subtracted from all
antigen-specific CD4+ T-cell responses. Statistical significance was
analysed by the Mann-Whitney U test (CD#350, n = 16; CD.350,
n = 15; HIV2, n = 31). The influenza immunity data from HIV-uninfected
adults and asymptomatic HIV-infected individuals has been reported in
part previously [11].
doi:10.1371/journal.pone.0038628.g001
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HAART in industrialised countries [25]. We have demonstrated
an impaired influenza-specific proliferative CD4+ T-cell response
and modest reconstitution in CD154 expression in individuals on
HAART for 6 months despite an increase in CD4 count and
a reduction in HIV viral load. This might be due to commence-
ment of HAART with a low CD4 count nadir, which has been
associated with partial immune reconstitution and poor outcome
[26]. It might also be that HAART alone is not sufficient to
reconstitute influenza-specific responses. This evidence of poor
immune influenza-specific reconstitution, suggests that HIV-
infected patients on HAART may be at risk to influenza-related
complications. Ensuring early commencement of HAART and
targeted vaccination strategies early on in the course of HIV
infection may help reduce the risk of influenza-related complica-
tions in this immunologically-susceptible group.
However, it has been shown that influenza-specific IgG
responses, as measured by antibody levels, are not impaired in
HIV-infected individuals following vaccination, irrespective of
CD4 count. In contrast, other studies in the subsequent years,
using hemagglutination-inhibition assay, have shown that follow-
ing vaccination with monovalent 2009 pandemic influenza A
(H1N1) vaccine; HIV-infected adults generated significantly
poorer antibody responses compared with HIV-uninfected persons
[27], and that, HIV-infected adults did not generate durable
seroprotective antibody response [28]. Future studies should
investigate the association between reduced naturally-acquired
influenza-specific CD4+ T-cell immunity and naturally-acquired
influenza-specific antibody responses in HIV-infected individuals.
The main limitation of our study is that we did not investigate
the effect of HIV and HAART on anti-influenza hemagglutinin
(HA) antibodies. However, recently, a study by Wilkinson et al. has
shown that in humans pre-existing influenza-specific CD4+ T-cells
and not influenza-specific CD8+ T cells were associated with lower
virus shedding and less severe illness in absence of detectable anti-
influenza antibodies [29]. This above-mentioned study highlights
the importance of CD4+ T-cell immunity in defence against
influenza infection and introduces possibilities for development of
influenza vaccines that will be able to target CD4+ T-cells, which
will then potentially provide cross-protection against different
influenza strains. Our study, therefore provides some evidence to
suggest that the impaired influenza-specific CD4+ T-cell immunity
may be responsible in part for the increased risk in influenza-
associated complications in HIV-infected persons.
In conclusion, healthy African adults have a robust influenza-
specific CD4+ T-cell immunity similar with other populations with
a known high prevalence rate of influenza infection. This
immunity is lost in HIV-infected adults and may increase the risk
of influenza-related complications. Although initiation of HAART
managed to suppress viral load and boost the CD4 count, it did
not restore the influenza-specific immunity even after 12months
on HAART, suggesting that this intervention alone may not
rapidly reduce the risk of influenza-related complications. These
data highlight the need to intensify influenza surveillance to
determine the burden of disease in immunologically-susceptible
African populations.
Supporting Information
Figure S1 Similar CD4+ T-cell proliferative responses to
a polyclonal stimulus in HIV-infected adults compared
to HIV-uninfected individuals. (A) Peripheral blood mono-
nuclear cells were stained with CFSE, stimulated with PHA for 7
days and proliferative responses were measured using flow
cytometry. Black horizontal bars represent median and IQRs
after background responses were subtracted. Statistical significance
was analysed by the Mann-Whitney U test (CD#350, n= 8;
CD.350, n = 7; HIV2, n = 10).
(TIF)
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Figure 2. Impaired immune reconstitution in influenza antigen-specific CD4+ T-cell responses in peripheral blood of HIV-infected
adults following HAART. (A) Peripheral blood mononuclear cells (PBMCs) were stained with CFSE, stimulated with influenza vaccine for 7 days and
proliferative responses were measured using flow cytometry (Baseline, n = 15; 6months, n = 14; 12months, n = 14; HIV2, n = 10) (B) PBMCs were
stimulated with influenza vaccine and the expression of CD154 on activated CD4+ T cells was measured using flow cytometry. Black horizontal bars
represent median and IQRs after background responses were subtracted from all antigen-specific CD4+ T cell responses (Baseline, n = 16; 6months,
n = 16; 12months, n = 11; HIV2, n = 11). Statistical significance was analysed by the Mann-Whitney U test.
doi:10.1371/journal.pone.0038628.g002
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